MDxHealth Inks Marketing Deal with LI Path for Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a co-marketing agreement with Long Island Pathology to promote MDxHealth's ConfirmMDx for Prostate Cancer test.

LI Path is an independent anatomic and clinical pathology lab serving the New York City metropolitan area, and MDxHealth expects the deal to expand its access to urologists in that market. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.